动态监测血清乳酸脱氢酶水平在急性白血病中的临床意义研究

doi:10.3969/j.issn.1673-8640.2014.06.011

摘要/Abstract

摘要： 目的通过动态监测急性白血病(AL)患者血清乳酸脱氢酶(LDH)水平,探讨LDH对AL患者病情监测和预后评估的临床意义。方法回顾分析初诊的1 184例AL患者的2 170例次LDH水平,评估患者LDH水平随疾病进程的变化趋势并探究其与AL的预后和疾病进展的关系,同时分析LDH与血细胞、骨髓白血病细胞比例、白血病融合基因和流式细胞术分型等相关辅助诊断指标的关系。结果 AL患者不同病程阶段的LDH水发平不同,其中初发组及复发组LDH水平明显高于缓解组及正常对照组(P<0.05)。缓解组LDH水平有所减低,但仍高于正常对照组(P<0.05)。急性淋巴细胞白血病(ALL)组LDH水平明显高于急性髓性白血病(AML)组(P<0.05)。与其他AL诊断及预后相关指标比较,LDH与骨髓白血病细胞百分数、白血病相关融合基因、细胞免疫分型等都有相关性(P<0.05)。结论不同病程阶段、不同亚型AL患者的血清LDH水平有差异,血清LDH水平可作为AL诊断、疾病进程及疗效评估的辅助指标。

关键词: 乳酸脱氢酶, 急性白血病, 诊断, 疾病进程, 疗效评估

Abstract: Objective To monitor dynamically serum lactate dehydrogenase (LDH) levels in acute leukemia (AL) patients,and to investigate the clinical significance on the monitoring of pathogenetic condition and prognosis evaluation. Methods The LDH levels of 2 170 times from 1 184 de novo AL patients were analyzed retrospectively. The relationship of LDH levels with disease progression and AL prognosis was evaluated.The relationships between LDH levels and blood cell counts,the proportion of bone marrow leukemia cells,cytogenetic abnormality, flow cytometry immunophenotyping and the other related diagnostic markers were analyzed. Results LDH levels of AL patients in different stages of the disease were different. The LDH levels of incipient and relapse stages in AL patients were significantly higher than those of remission stage in AL patients and those in healthy controls (P<0.05). The LDH levels of remission stage in AL patients reduced, but were still significantly higher than those in healthy controls (P<0.05). The LDH levels of acute lymphoblastic leukemia (ALL) patients were significantly higher than those of acute myeloid leukemia (AML) patients (P<0.05). Compared with the other diagnostic and prognostic indicators of AL, LDH levels had correlation with the proportion of bone marrow leukemia cells,cytogenetic abnormality and flow cytometry immunophenotyping (P<0.05). Conclusions The serum LDH levels of AL patients in different stages and different subtypes are different significantly. The LDH levels can be used as a supplementary indicator of AL diagnosis, disease progression and therapeutic effect evaluation.

Key words: Lactate dehydrogenase, Acute leukemia, Diagnosis, Disease progression, Therapeutic effect evaluation

中图分类号:

Q554

刘华,郑沁,曾婷婷,叶远馨,李贵星,粟军. 动态监测血清乳酸脱氢酶水平在急性白血病中的临床意义研究[J]. 检验医学, 2014, 29(6): 622-626.

LIU Hua, ZHENG Qin, ZENG Tingting, YE Yuanxin, LI Guixing, SU Jun. Clinical significance on the dynamic monitoring of serum lactate dehydrogenase levels in acute leukemia[J]. , 2014, 29(6): 622-626.

参考文献

[1] Estey E,Dhner H. Acute myeloid leukaemia[J] . Lancet,2006,368(9550): 1894-1907.
[2] Chen CY,Cheng A,Huang SY,et al. Clinical and microbiological characteristics of perianal infections in adult patients with acute leukemia[J] . PLoS One,2013,8(4):e60624.
[3] Shima T,Miyamoto T,Kikushige Y,et al. Quantitation of hematogones at the time of engraftment is a useful prognostic indicator in allogeneic hematopoietic stem cell transplantation[J] . Blood,2013,121(5):840-848.
[4] Teng CL,Young JH,Hsu SL,et al. Lactate dehydrogenase, not vascular endothelial growth factor or basic fibroblast growth factor,positively correlates to bone marrow vascularity in acute myeloid leukemia[J] . J Clin Med Assoc,2006,69(11):534-537.
[5] Wimazal F, Sperr WR, Kundi M, et al. Prognostic value of lactate dehydrogenase activity in myelodysplastic syndromes[J] . Leuk Res, 2001,25(4):287-294.
[6] Satoh Y,Matsumura I,Tanaka H,et al. C-terminal mutation of RUNX1 attenuates the DNA-damage repair response in hematopoietic stem cells[J] . Leukemia,2012,26(2):303-311.
[7] Chou FS,Griesinger A,Wunderlich M,et al. The thrombopoietin/MPL/Bcl-xL pathway is essential for survival and self-renewal in human preleukemia induced by AML1-ETO[J] . Blood,2012,120(4):709-719.
[8] Renneville A,Boissel N,Nibourel O,et al. Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association[J] . Leukemia,2012,26(6):1247-1254.
[9] Urayama KY,Chokkalingam AP,Manabe A,et al. Current evidence for an inherited genetic basis of childhood acute lymphoblastic leukemia[J] . Int J Hematol,2013,97(1):3-19.
[10] McBride A,Westervelt P. Recognizing and managing the expanded risk of tumor lysis syndrome in hematologic and solid malignancies[J] . J Hematol Oncol,2012,5:75.
[11] Yi JH,Kim JH,Baek KK,et al. Elevated LDH and paranasal sinus involvement are risk factors for central nervous system involvement in patients with peripheral T-cell lymphoma[J] . Ann Oncol,2011, 22(7):1636-1643.
[12] Martínez-Laperche C,Gómez-García AM,Lassaletta , et al. Detection of occult cerebrospinal fluid involvement during maintenance therapy identifies a group of children with acute lymphoblastic leukemia at high risk for relapse[J] . Am J Hematol, 2013,88(5):359-364.
[13] Portell CA,Sweetenham JW. Adult lymphoblastic lymphoma[J] . Cancer J,2012,18(5):432-438.
[14] Alves GV,Fernandes AL,Freire JM,et al. Flow cytometry immunophenotyping evaluation in acute lymphoblastic leukemia: correlation to factors affecting clinic outcome[J] . J Clin Lab Anal,2012,26(6):431-440.
[15] Chen SW,Li CF,Chuang SS,et al. Aberrant co-expression of CD19 and CD56 as surrogate markers of acute myeloid leukemias with t(8;21) in Taiwan[J] . Int J Lab Hematol,2008,30(2):133-138.
[16] Abdelhaleem M. Frequent but nonrandom expression of lymphoid markers on de novo childhood acute myeloid leukemia[J] . Exp Mol Pathol,2007,83(2):259-263.
[17] Estey EH. Acute myeloid leukemia: 2013 update on risk-stratification and management[J] . Am J Hematol,2013,88(4):318-327.
[18] 包书萌,李永哲. 急性白血病预后不良相关基因研究进展[J] . 国际检验医学志,2008,29(9):819-820.
[19] Gmidène A,Sennana H,Wahchi I,et al. Cytogenetic profile of a large cohort of Tunisian de novo acute myeloid leukemia[J] . Hematology,2012,17(1):9-14.
[20] Yan J,Wang K,Dong L,et al. PML/RARalpha fusion protein transactivates the tissue factor promoter through a GAGC-containing element without direct DNA association[J] . Proc Natl Acad Sci USA,2010,107(8):3716-3721.
[21] Martinelli G,Rondoni M,Buonamici S,et al. Molecular monitoring to identify a threshold of CBFbeta/MYH11 transcript below which continuous complete remission of acute myeloid leukemia inv16 is likely[J] . Haematologica,2004,89(4):495-497.
[22] De Braekeleer E,Douet-Guilbert N,Rowe D,et al. ABL1 fusion genes in hematological malignancies: a review[J] . Eur J Haematol,2011,86(5):361-371.
[23] Holmlund T,Lindberg MJ,Grander D,et al. GCN5 acetylates and regulates the stability of the oncoprotein E2A-PBX1 in acute lymphoblastic leukemia[J] . Leukemia,2013,27(3):578-585.
[24] Tamai H,Miyake K,Yamaguchi H,et al. Resistance of MLL-AFF1-positive acute lymphoblastic leukemia to tumor necrosis factor-alpha is mediated by S100A6 upregulation[J] . Blood Cancer J,2011,1(11):e38.
[25] 张延清,戴海滨,王京华,等. 连续动态观察乳酸脱氢酶对MDS预后判定的意义[J] .中国实验血液学杂志,2011,19( 1):85-89.
[26] 高绍华. 血清LDH、HBDH水平与急性白血病患者临床转归的关系[J] .武警医学院学报,2009,15(4):341-342.